Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

BACKGROUND: The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:medRxiv
Autores principales: Senefeld, Jonathon W., Johnson, Patrick W., Kunze, Katie L., van Helmond, Noud, Klassen, Stephen A., Wiggins, Chad C., Bruno, Katelyn A., Golafshar, Michael A., Petersen, Molly M., Buras, Matthew R., Klompas, Allan M., Sexton, Matthew A., Soto, Juan C. Diaz, Baker, Sarah E., Shepherd, John R.A., Verdun, Nicole C., Marks, Peter, van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Rea, Robert F., Herasevich, Vitaly, Whelan, Emily R., Clayburn, Andrew J., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Vogt, Matthew N.P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Wright, Katherine, Greenshields, Joel T., Paneth, Nigel S., Fairweather, DeLisa, Wright, R. Scott, Casadevall, Arturo, Carter, Rickey E., Joyner, Michael J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043472/
https://ncbi.nlm.nih.gov/pubmed/33851175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.08.21255115
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares